Tag Archives: RESI

RESI Boston Summer, June 4, 2018 – Program Guide Is Here!

31 May

By Nono Hu, Director of Marketing, LSN

In 4 days, The Redefining Early Stage Investments (RESI) Conference will kick off a bustling week for the global healthtech industry in Boston. At RESI Boston, over 300 investors will be under one roof in search of compelling connections with early stage companies.

Check out the program guide now to plan for a productive day at RESI packed with partnering meetings, innovative technologies, and up-to-date investment knowhow.

See you at RESI on June 4th at the Boston Marriott Copley Place!

RESI Spotlight: Investors Focusing on Innovative Technologies For Mental & Behavioral Health

31 May

By Christine A. Wu, Senior Research Analyst, LSN


While mental and behavioral health conditions are highly prevalent, they are also often stigmatized. In the healthcare technology arena, this indication area has been on the rise in both excitement and innovation. According to the World Health Organization, one out of four people in the world suffer from a mental or neurological disorder, including a total of about 450 million people with mental disorders. Even as one of the leading causes of ill-health and disability worldwide, mental illness carries with it stigma, discrimination, and neglect, preventing patients from admitting the need for help, reaching for help or having the accessibility to resources for when they do. In a society that shies away from vulnerability, it becomes easy for us to not embrace the need for mental health or fully understand how to prevent future cases.

Industry and investors have responded; with the growth of the digital health vertical, the amount of capital invested in the mental and behavioral healthcare space has increased significantly. This year, the industry has seen deals as high as $40M in digital health platforms streamlining patients and mental health clinicians, mobile apps with professional coaching, and software solutions to overcome anywhere from anxiety and depression to eating disorders and substance abuse. As chronic diseases such as diabetes and inflammatory bowel disease can be debilitating for patients both medically and psychologically, behavioral health solutions include disease management IT platforms to monitor and improve treatment adherence. With the aim to treat individuals holistically, such platforms connect patients, mental health professionals, and medical physicians, tracking the patient’s physical and mental health as the disease progresses.

At RESI Boston Summer on Monday, June 4th, the LSN team is launching an initiative to highlight investment in mental and behavioral health with a new expert panel of VCs, pharma, hospital and healthcare systems.

Moderated by Julie Papanek Grant, Partner at Canaan Partners, the panel includes:

  • Justin Baker, Scientific Director, The McLean Institute for Technology in Psychiatry
  • Ken Duckworth, Senior Medical Director for Behavioral Health, Blue Cross Blue Shield of MA
  • Robert Garber, Partner, 7wire Ventures
  • Eric Schaeffer, Senior Director, Neuroscience Innovation, Johnson & Johnson Innovation

Panelists will provide their diverse perspectives of industry (and academia) trends in mental and behavioral health, its future outlook, and global impact.

The LSN team has also slated a handful of digital health companies in mental and behavioral health for the RESI Innovation Challenge.

Register for RESI and be sure to meet and learn both the investor side and company side of this up-and-coming space!


RESI Boston Summer Presents Innovation Challenge Finalists From Around The World

24 May

By James Huang, Research Analyst, LSN


We are excited to showcase the top RESI Innovation Challenge startup applicants, who will be taking part in the poster presentation showcase at the second annual RESI BIO held in Boston this year, alongside the BIO International conference. These handpicked companies represent the key sectors of the healthcare space including therapeutics, medical devices, diagnostics and digital health, and were selected based on their scientific/technical merit and commercial viability. Additionally, this Innovation Challenge will feature select companies from Korea and Taiwan to showcase innovation that is also occurring overseas.

The Innovation Challenge companies will compete for each attendee’s RESI Cash tokens throughout the day, which serves as a vote of their potential. The top 3 companies will win additional RESI tickets to events of their choosing and a feature in the LSN newsletter (20,000 readership), giving them access to hundreds of additional investors and ultimately enhancing their likelihood of securing an investment. Make sure to visit the exhibition hall to meet the RESI innovators and “invest” in your favorites!



MedTech Device

Digital Health

RESI Boston Summer 2018 Panel Announcement: Corporate Venture Capital

24 May

By Cole Bunn, Director of Research, LSN


Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Reza Halse, President, MRL Ventures, this panel will feature:

By registering for RESI Boston, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

In Partnership with KOTRA: Uncovering the Korean Biotech Start-Up Scene at RESI Boston

17 May

By Claire Jeong, Research Analyst, LSN


Even with the RESI Boston conference less than 3 weeks away, the upcoming conference continues to attract an international crowd of early-stage companies and investors. In last week’s newsletter, we discussed how over 1/3 of the registered attendees are coming from firms based outside of the USA. For this particular event, Life Science Nation (LSN) has been working closely with the Korea Trade-Investment Promotion Agency (KOTRA) to showcase innovative technologies from South Korea across therapeutics, medical devices, diagnostics, and digital health.

The Korean biotech ecosystem has certainly been growing in all aspects. This year, the government has pledged to invest over $328M (USD) to support the development of new biotech (1). For many years, South Korea has been well-established as a R&D hub – beyond the capital city of Seoul, other cities to keep an eye on include Songdo International City (home to large biotech companies, including Celltrion and Samsung BioLogics) and Daejeon (home to KAIST and a newly established biocluster, the DAEJEON Bio Venture Town). An increasing number of pharmaceutical groups are seeking innovations globally for in-licensing and equity investment. Some groups, like Yuhan Corporation, are planning to expand their operations in the USA, among other developed nations (2).

With these series of recent developments that have been contributing to the growth of Korean biotech/healthcare technologies, it is only natural that more start-up companies are seeking to meet and partner with global firms. Without further ado, here are the Korean companies that are attending and available to meet at RESI Boston!

Korea Trade-Investment Promotion Agency (KOTRA):
KOTRA, a global business platform, supports small and medium-sized Korean enterprises to explore overseas markets through its 127 offices/networks in 87 countries around the world. This year, KOTRA has partnered with KoreaBio (Korea Biotechnology Industry Organization), KIMST (Korea Institute of Marine Science & Technology Promotion) and COMPA (Commercialization Promotion Agency for R&D Outcome) in presenting a number of promising Korean biotech startups to the world. KOTRA strives to share its expertise and collaborate with these organizations to help biotech startups succeed, continue to grow, and expand its business abroad.

Korean Free Economic Zones (K-FEZ):
Korean Free Economic Zones are specially designated areas created to improve the business and living environment for foreign-invested firms in Korea. Since the 2003 inauguration of an FEZ in Incheon, the number of FEZs in operation has grown to eight: Incheon, Busan-Jinhae, Gwangyang Bay Area, Daegu-Gyeongbuk, Saemangeum-Gunsan, Yellow Sea, East Coast and Chungbuk.

Deep Medi Inc:
DeepMedi developed the first monitor able to read blood pressure from only a smart phone camera without additional special  equipment. Using their artificial intelligence based model, the user can estimate blood pressure from a pulse wave.

L-BASE has developed new peptide drugs for multi-drug-resistance cancers. By controlling the function of a new CTA (Cancer-Testis Antigen), CAGE, these peptide drug candidates can solve multi-drug resistances in cancer, especially lung cancer with T790M mutation and breast cancer. These drug candidates are a first in class in multi drug resistance and now at the stage of IND preparation. L-BASE has published more than 15 international papers on CAGE functions, and has applied for several IPs about peptides drug candidates which control CAGE function.

CellSafe is developing the first bone graft products with dual functions of bone formation and the inhibition of bone destruction which will replace BMP2 (Bone morphogenetic protein 2) products.


MDimune is developing innovative therapeutics for cancer and COPD in order to solve the highly unmet medical needs with BioDrone® technology, which is a target specific drug delivery platform based on artificial exosomes derived from human cells such as immune cells and stem cells.

NosQuest, Inc:

NosQuest is a diagnostics company that develops analytical software and databases to identify microorganisms as well as to diagnose stages of diseases (currently breast & ovarian cancers).  NosQuest is also developing an artificially intelligent cloud-based platform for library diagnostics where hospitals and eventually, patients can access the platform for diagnosis/prognosis.

RADIANQBiO offers breakthrough on-site microchip platforms in resource-poor settings for solving many global heath care challenges, such as rapid detection & prevention of foodborne and waterborne pathogens, to broaden access to unrestricted healthcare & pharmaceutical services, e.g. super-easy platforms for rapid drug screening & clinical trials.


PANAGENE is a sole provider of PNA (DNA analogue) for commercial use and has its own technologies for mass production and various application of PNA. PANAGENE’s diagnostic products are used to identify personalized medicine for patients with various cancer and to detect infectious diseases. Also, PANAGENE developed the first in class detection kit in liquid biopsy in Korea.

Optolane Technologies Inc:
OPTOLANE is a semiconductor integrated In-Vitro Diagnostic (IVD) platform company that is developing POC-MDx solutions of real-time PCR (qPCR) and digital PCR (dPCR) system by using CMOS sensor based technology.

THE WAVE TALK developed a laser-based sensor detects any impurity (including bacteria), even in running water, and continuously and non-disruptively sends a signal to any device, including mobile applications. Their laser-based sensor is extremely more accurate than conventional lasers and is able to detect even low concentrations of bacteria based on its movements in real-time.

Infit & Company Inc:
Infit & Company Inc. was established on the disruptive biological tissue-analyzing technology to fulfill new paradigm of healthcare. Quantified and physiological value will be used in various wellness and medical applications such as belly fat scanner, breast cancer diagnosis device.

ImmuneMed Inc:

ImmuneMed was established in 2000 as one of the pioneer biotech venture companies in Korea. The platform technology of ImmuneMed is phenotype-based excavation of antigen & antibody. First in class anti-viral immunoglobulin (IgG4) drug candidate is effective for hepatitis B, hepatitis C, influenza and dermatitis. Original IP of drug candidate was issued in 2004 and Material IP was applied in Korea and 8 regions around the globe (2016).

Quratis Inc:

Established in 2016 as a venture company, Quratis works as an important base for research partners to cover the Asian region including China with its TB vaccine and other products. Quratis, which has a long-term joint research project with Yonsei University Health System, concluded an exclusive license agreement with research partners for a tuberculosis vaccine in 2017.

Bally’s Co., Ltd:
This young social venture company manufactures pet food by up-cycling agricultural and fisheries products, which are undervalued with its corporate mission of “no life to be dumped”.


Finding Investment Opportunities At RESI: An Interview with Andy Li (Biosense Global)

17 May

Andy Li

An interview with Andy Li, CEO & President, Biosense Global

– By Jessica Yang, Investor Research Analyst, LSN

Jessica Yang

Earlier this week, I had the pleasure of speaking with Dr. Andy Li, the founding partner of Biosense Global LLC. Andy has attended nearly every RESI event in the last 2 years. RESI is a partnering event that enables early-stage life science, MedTech and digital health companies to meet and interact with investors and strategic partners based on mutual fit. Recently, we learned that Biosense Global has invested in two companies that Andy first met at RESI.

In this interview, Andy discusses his perspectives on his RESI experiences, Biosense Global’s investments in companies attended RESI, and some suggestions for fundraising CEOs.

Jessica: To begin, please tell us a little bit about your background and your fund.

Andy: My name is Andy Li, and I am the founding partner of Biosense Global LLC. I have more than 25 years of biomedical research and biopharmaceutical industry experience with proven track records in global drug development in multiple therapeutic areas, alliance management, and business development. Currently, Biosense Global invests in early to mid-stage biopharma and Medtech projects. With our R&D facilities in China, in-licensing assets from the U.S. and Europe to China would be an important consideration.

Jessica: How many RESI conferences have you attended? What was your first impression of the RESI Conference series?

Andy: I’ve attended RESI conference six times to date, and the upcoming Boston one will be the seventh. One thing I enjoyed about attending RESI is that I think RESI attracts early-stage companies with good qualities. The companies I met in the previous RESI have solid science and great teams, and RESI allows investors and companies from around the globe to build connections easily.

Jessica: What successes have you experienced through RESI?

Andy: We’ve invested in a company focusing on immuno-oncology that I first met in RESI. The company is called PrimeVax, and this company uses a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting. In addition, we’ve invested in another company call Curtana Pharmaceuticals. I met this company at a previous RESI conference, and we continued a great relationship that eventually led to an investment. Curtana is developing therapies for the treatment of brain cancer, including glioblastoma in adults and pediatric high grade glioma in children.

Jessica: In your opinion, what are the greatest strengths of RESI?

Andy: RESI is a well-organized conference, especially in its online partnering system. Compare to many conferences I’ve attended before; I think RESI has a solid platform that allows investors to have a better understanding of attending companies and book meetings easily online. Also, since Life Science Nation has great connections with many companies in your platform, I think this helps you in organizing the RESI conference, and your significant portion of company connections also help us to find ideal companies that match our investment criteria. Another thing is that I think you choose great times to hold RESI conferences, for example, you hold RESI concurrent with BIO or JPM, and this attracts investors to attend all these events at one time to reduce travel inconvenience.

Jessica: What were some aspects that differentiated the companies you’ve invested in vs. others?

Andy: Overall, I’ll look at three aspects. First and the most important one to me is whether the company’s technology is unique and innovative. Second, I’ll look at the company’s management team – I prefer a solid team with relevant experiences. Last, I think it’s also essential that the company’s investment value is reasonable.

Jessica: How can companies better prepare for an initial meeting with your group?

Andy: Sometimes, early-stage companies that founded by scientist-entrepreneurs may only focus on the technologies. I’ll suggest companies try to touch on technology, IP, commercial potential (more important for not well-known indications), competitor analysis, and fundraising plans, etc.

Jessica: Do you have any suggestions for RESI?

Andy: It would be great for you to give suggestions for attending companies to know what aspects they can cover in their presentations and slide decks. This will help increasing companies’ qualities in RESI.

About Biosense Global LLC:

BioSense Global, LLC is an NJ-based venture investment firm that was founded in 2016 and focused on bridging Eastern and Western innovations and investment opportunities. Biosense invests in early to mid-stage biopharma and medtech projects. In addition, the company has R&D operations in China. Biosense is currently looking for new opportunities globally.

Big Pharmas Explain Partnering Strategy At RESI On June 4th

17 May

By Lucy Parkinson, VP of Investor Research, LSN

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines.  RESI has become a venue for these major players to make connections with early stage biotech companies, and RESI includes a panel on Big Pharma to provide entrepreneurs with an opportunity to learn directly from experienced pharma scouts on how to find the right partner and get a deal made.

This panel will feature five speakers from various big pharma companies discussing topics such as:

  •     How does big pharma source these assets?
  •     How does the evaluation and investment process work?
  •     How can a startup position themselves to make a deal?
  •     What are some key factors that big pharma companies look for?
  •     How early stage is big pharma willing to look?

These panelists will shed some light on the process that big pharma goes through when sourcing early stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.

The panelists are:

  • Aaron Schwartz, Director, R&D Innovation Sourcing, Novo Nordisk
  • Brian Bronk, Head of External Innovation, Rare Diseases, Sanofi
  • Murali Gopalakrishnan, Sr. Director, Head Search & Evaluation Neuroscience, AbbVie
  • Nicola La Monica, Senior Director, Infectious Diseases and Vaccines Scientific Innovation, Johnson & Johnson Innovation, Boston
  • Yvonne Kobayashi, Sr Director, Emerging Technology & Innovation, Eli Lilly & Co

%d bloggers like this: